TLDR
- Biogen has signed a multi-target collaboration with Alloy Therapeutics to use Alloy’s AntiClastic™ ASO platform for antisense drug development.
- The deal covers multiple undisclosed targets; Alloy gets an upfront payment plus milestone payments and tiered royalties.
- Biogen and Alloy have had a working relationship since 2020, previously focused on antibody treatments.
- RBC Capital cut its Biogen price target to $213 from $233, but kept an Outperform rating.
- The average analyst price target for BIIB sits at $210.30, with a consensus overweight rating.
Biogen has signed a new collaboration deal with Alloy Therapeutics, giving Biogen access to Alloy’s AntiClastic™ antisense oligonucleotide (ASO) platform across multiple undisclosed drug targets.
Alloy will receive an upfront payment under the agreement, along with eligibility for milestone payments and tiered royalties if any products come to market.
The two companies have worked together since 2020, but that earlier relationship was focused on antibody treatments. This new deal moves into genetic medicine territory.
Biogen already has a track record in ASO drugs. Its Spinraza, used to treat spinal muscular atrophy, is one of the more established ASO therapies on the market. The new deal is aimed at building on that foundation using Alloy’s platform.
Alloy CEO Errik Anderson described the tie-up in direct terms: “Biogen is a leader in the space and has made huge contributions to ASO technologies. We view this as validation and an opportunity to build on their experience.”
Alloy’s goals for the platform in this collaboration are focused on three things: greater potency, improved immunogenicity, and enhanced tissue targeting.
Alloy’s Growing Track Record
Alloy, based in Waltham, Massachusetts, has built its model around partnering with biopharma companies throughout drug discovery and development. Since 2017, it has signed roughly 200 collaborations, more than 100 of which have resulted in licensed therapeutic candidates.
Twenty-two drugs developed through Alloy’s platform have reached clinical trials. Last year, Sanofi signed a deal worth up to $400 million to use the same ASO platform in the hunt for a potential central nervous system therapy.
Christian Cobaugh, CEO of Alloy’s Genetic Medicine Division, said the Biogen deal will help the firm move beyond early-stage discovery into more downstream elements of drug development.
Unlike many platform biotechs that rely on partnerships to fund their own drug pipeline, Alloy has built its business around collaboration as the core model.
Analyst View on Biogen
On the analyst side, RBC Capital lowered its price target on BIIB to $213 from $233 on April 7, while keeping an Outperform rating on the stock.
Across analysts polled by FactSet, the average price target on Biogen stands at $210.30, with a consensus overweight rating.
BIIB was down 2.82% on the day the deal was announced.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
